sorafenib has been researched along with phenylalanine in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (phenylalanine) | Trials (phenylalanine) | Recent Studies (post-2010) (phenylalanine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 23,695 | 721 | 4,367 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imramovský, A; Kryštof, V; Páchniková, G; Slaninová, I; Uldrijan, S | 1 |
| Choi, HJ; Hong, HE; Hong, TH; Jeena, MT; Kim, KH; Kim, OH; Kim, SJ; Lee, KH; Ryu, JH | 1 |
2 other study(ies) available for sorafenib and phenylalanine
| Article | Year |
|---|---|
Substituted 2-hydroxy-N-(arylalkyl)benzamide sensitizes cancer cells to metabolic stress by disrupting actin cytoskeleton and inhibiting autophagic flux.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylalanine; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Stress, Physiological; Wound Healing | 2016 |
Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mitochondria; Organophosphorus Compounds; Peptides; Phenylalanine; Pyrenes; Reactive Oxygen Species; Sorafenib | 2021 |